Graham Capital Management L.P. Grows Stock Holdings in Xeris Biopharma Holdings, Inc. $XERS

Key Points

• Graham Capital Management L.P. increased its holdings in Xeris Biopharma by 89.2% in Q1, now owning 133,668 shares valued at approximately $734,000.
• Xeris Biopharma reported a net profit of ($0.01) per share for the last quarter, exceeding analyst estimates of ($0.03) per share, with revenues of $67.71 million.
• Analysts have recently upgraded Xeris Biopharma's stock rating to "strong-buy" with price targets raised, including a target of $10.00 from HC Wainwright.

Graham Capital Management L.P. boosted its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 89.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 133,668 shares of the company's stock after acquiring an additional 63,006 shares during the period. Graham Capital Management L.P. owned about 0.09% of Xeris Biopharma worth $734,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of XERS. R Squared Ltd increased its stake in shares of Xeris Biopharma by 27.7% during the 1st quarter. R Squared Ltd now owns 15,730 shares of the company's stock worth $86,000 after purchasing an additional 3,410 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Xeris Biopharma by 4.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,388 shares of the company's stock worth $273,000 after buying an additional 3,447 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Xeris Biopharma by 31.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 16,268 shares of the company's stock worth $55,000 after acquiring an additional 3,847 shares during the last quarter. Apollon Wealth Management LLC raised its holdings in shares of Xeris Biopharma by 19.8% in the first quarter. Apollon Wealth Management LLC now owns 24,160 shares of the company's stock worth $133,000 after acquiring an additional 4,000 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Xeris Biopharma by 5.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 170,482 shares of the company's stock valued at $578,000 after acquiring an additional 9,506 shares in the last quarter. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently commented on XERS shares. Leerink Partners lifted their price objective on Xeris Biopharma from $7.00 to $9.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 19th. HC Wainwright initiated coverage on shares of Xeris Biopharma in a report on Tuesday, August 12th. They set a "buy" rating and a $10.00 price target for the company. Finally, Wall Street Zen downgraded shares of Xeris Biopharma from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 5th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Xeris Biopharma presently has a consensus rating of "Moderate Buy" and a consensus target price of $7.08.

Insider Activity at Xeris Biopharma

In other news, insider Kevin Mcculloch bought 25,000 shares of Xeris Biopharma stock in a transaction that occurred on Friday, June 13th. The shares were purchased at an average price of $4.38 per share, for a total transaction of $109,500.00. Following the completion of the acquisition, the insider owned 1,708,585 shares of the company's stock, valued at $7,483,602.30. The trade was a 1.48% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey W. Sherman sold 42,232 shares of the company's stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $7.92, for a total value of $334,477.44. Following the sale, the director owned 219,188 shares of the company's stock, valued at $1,735,968.96. This represents a 16.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 192,232 shares of company stock worth $1,430,777 in the last 90 days. Company insiders own 6.47% of the company's stock.

Xeris Biopharma Trading Up 1.7%

XERS traded up $0.13 during midday trading on Wednesday, hitting $7.81. The company's stock had a trading volume of 1,193,348 shares, compared to its average volume of 2,017,068. Xeris Biopharma Holdings, Inc. has a 52-week low of $2.66 and a 52-week high of $8.03. The firm has a 50-day moving average price of $6.37 and a two-hundred day moving average price of $5.22. The firm has a market cap of $1.26 billion, a P/E ratio of -37.19 and a beta of 0.13.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.02. The company had revenue of $67.71 million during the quarter, compared to analyst estimates of $64.58 million. On average, equities analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.